Kawasaki Disease After Vaccination: Reports to the Vaccine Adverse Event Reporting System 1990-2007

Wei Hua, MD, PhD; Hector S. Izurieta, MD, MPH; Barbara Slade, MD; Ermias D. Belay, MD; Penina Haber, MPH; Rosemary Tiernan, MD, MPH; Emily Jane Woo, MD, MPH; John Iskander, MD, MPH; M. Miles Braun, MD, MPH; Robert Ball, MD, MPH, ScM


Pediatr Infect Dis J. 2009;28(11):944-947. 

In This Article


Although data from prelicensure clinical trials revealed higher (not statistically significant) rates of KD among RotaTeq vaccines compared with placebo, our analysis of postmarketing data does not suggest an elevated risk of KD for RotaTeq or other US-licensed vaccines. Continued postmarketing monitoring for KD, including observational studies, are ongoing.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.